Agilon Health Class Action Lawsuit
Analysis based on 7 articles · First reported Jan 28, 2026 · Last updated Feb 26, 2026
The market is negatively impacted by the news of Agilon Health's CEO departure, missed financial estimates, and the subsequent class action lawsuit, leading to a significant drop in Agilon Health's stock price. This event highlights the risks associated with investing in companies with potentially misleading financial guidance.
Glancy Prongay Wolke & Rotter LLP has reminded investors of an upcoming deadline to file a lead plaintiff motion in a class action lawsuit against Agilon Health. The lawsuit alleges that Agilon Health made materially false and/or misleading statements to investors between February 26, 2025, and August 4, 2025. Specifically, the complaint claims that Agilon Health recklessly issued unachievable guidance for 2025 and overstated the positive financial impact of its strategic actions. These allegations arose after Agilon Health announced on August 4, 2025, that its President, CEO, and Director of the Board was departing, and simultaneously released second-quarter 2025 financial results that missed estimates. The company also suspended its 2025 guidance, citing leadership change, ongoing initiatives, and market uncertainty. Following this news, Agilon Health's stock price fell by 51.5%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard